| Literature DB >> 28241747 |
Angélica Mera-Ramírez1, Andrés Castillo2, Yenifer Orobio1, María Adelaida Gómez1, Carolina Gallego-Marin3,4.
Abstract
BACKGROUND: Clinical manifestations of cutaneous leishmaniasis (CL) caused by Leishmania (Viannia) range from asymptomatic infection to self-limited, or chronic (non-healing) cutaneous lesions. Given the critical role of the immune response in the clinical outcome of CL, it is plausible that functional polymorphisms in immune-related genes contribute to define the clinical manifestations of human infection.Entities:
Keywords: Asymptomatic infection; Chronicity; Cutaneous leishmaniasis; Single nucleotide polymorphism
Mesh:
Substances:
Year: 2017 PMID: 28241747 PMCID: PMC5330139 DOI: 10.1186/s12879-017-2281-4
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Baseline characteristics of the study groups
| Characteristic | Asymptomatic infection | Chronic cutaneous leishmaniasis |
|---|---|---|
| Age-years. Mean (range) | 43 (17–67) | 31 (9–69) |
| Sex: | ||
| Male; % ( | 58.3 (21) | 55.3 (21) |
| Female; % ( | 41.7 (15) | 44.7 (17) |
| Positive lympho-proliferation assay; % ( | 100 (36) | 15.8 (6) |
| Montenegro skin test zone, mm. Mean (range) | N/A | 13.25 (10–18) |
| Number of lesion; median (range) | N/A | 2.2 (1–10) |
| Time of evolution of older lesion, months; median (range) | N/A | 16.3 (4–72) |
| Type of lesions: % ( | ||
| Ulcer | N/A | 71.1 (27) |
| Plaque | N/A | 5.3 (2) |
| Nodule | N/A | 7.9 (3) |
| Not determined | N/A | 15.8 (6) |
| Patients from whom | N/A | 34.2 (13) |
|
| N/A | 100 (13) |
| Not determineda | N/A | 65.8 (25) |
Abbreviations: N/A not applicable
aNot determined because no strain was isolated
Primer sequences and restriction endonucleases used for RFLP analysis and fragment sizes for identification of SNPs
|
|
|
|
|
|---|---|---|---|
|
| F, 5- TCA TTC TAT GTG CTG GAG ATG G -3 |
| CC: 125 + 84 |
| R, 5- TTT GGG GGA AGT GGG TAA GAG T -3 | |||
|
| F, 5- AGG CAA TAG GTT TTG AGG GCC AT -3 |
| GG: 96 + 20 |
| R, 5- ACA CTC CCC ATC CTC CCT GCT -3 | |||
|
| F, 5- GAT TAG CAT ATC TAG ACT ACT ACC TCC ATG -3 |
| AA: 248 |
| R, 5- GAT CAA CTT CTG AAA AAG CAT TCC CAC -3 | |||
|
| F, 5 -GGT TGC TGT TCT CAA AGT GAT TTT GGG AGA A- 3 |
| CC: 406 |
| R, 5 -ACC TGA AGA CTG GAG AGT GAG TTA AAT GTT- 3 |
Genotype, allele frequency and MAF of TNFα, IL-10 and TLR4 gene polymorphisms in individuals with chronic and asymptomatic cutaneous leishmaniasis
| SNPs | Frequency; |
| OR (95% CI) | ||
|---|---|---|---|---|---|
| Asymptomatic | CCL | ||||
| TNFα-308 | |||||
| Genotype | AA | 1 (4) | 0 (0) | 0.45 b | 0 (0–0) |
| GG | 20 (71) | 29 (85) | 0.06 a | 0.39 (0.14–1.05) | |
| GA | 7 (25) | 5 (15) | 0.30 a | 1.93 (0.54–0.94) | |
| Allele | A | 9 (16) | 5 (7) | 0.13 a | 2.41 (0.76–7.67) |
| G | 47 (87) | 63 (93) | 0.13 a | 0.41 (0.13–1.32) | |
| MAF | 0.161 | 0.074 | 0.126 a | ||
| IL-10-819 | |||||
| Genotype | CC | 6 (27) | 11 (34) | 0.21 a | 0.49 (0.16–1.51) |
| TT | 9 (41) | 16 (50) | 0.51 a | 0.69 (0.23–2.07) | |
| CT | 7 (32) | 5 (16) | 0.16 a | 2.52 (0.68–9.33) | |
| Allele | C | 19 (43) | 27 (42) | 0.92 a | 1.04 (0.48–2.26) |
| T | 25 (57) | 37 (58) | 0.92 a | 0.96 (0.44–2.09) | |
| MAF | 0.568 | 0.578 | 0.918 a | ||
| TLR4 Asp299Gly | |||||
| Genotype | AA | 28 (85) | 28 (85) | 0.45 b | 1.25 (0.38–4.22) |
| GG | 0 (0) | 0 (0) | – | – | |
| AG | 5 (15) | 5 (15) | 0.63 b | 1.00 (0.20–4.88) | |
| Allele | A | 61 (92) | 61 (92) | 0.63 b | 1.00 (0.22–4.58) |
| G | 5 (8) | 5 (8) | 0.63 b | 1.00 (0.22–4.58) | |
| MAF | 0.076 | 0.076 | 1.000 a | ||
| TLR4 Thr399Ile | |||||
| Genotype | CC | 34 (100) | 34 (100) | – | – |
| TT | 0 (0) | 0 (0) | – | – | |
| CT | 0 (0) | 0 (0) | – | – | |
| Allele | C | 68 (100) | 68 (100) | – | – |
| T | – | – | – | – | |
| MAF | 0.000 | 0.000 | – | ||
a Chi square test
b Fisher exact test (one-tail)